SES Logo

SYSTEMIC ENZYME SUPPORT.org

 

Scientific References

 Systemic Enzyme Poster References
small-poster
 

Please use our Search feature to find pacific information about systemic enzyme support and conditions treated.

 

 

 [1] - Crystallography derived from RCSB Protein Data Bank. Located at: http://www.rcsb.org/pdb/home/home.do
Accessed: 06/19/08.

[2] - EC Numbers. “Recommendations of the Nomenclature Committee of the International Union of Biochemistry and Molecular Biology on the  Nomenclature and Classification of Enzymes by the Reactions they Catalyse”. Located at: http://www.chem.qmul.ac.uk/iubmb/enzyme/   Accessed: 06/19/08.

[3] - Gonias SL, Pizzo SV. Conformation and protease binding activity of binary and tertiary human alpha 2-macroglobulin-protease complexes. J Biol Chem. 1983 Dec 10;258(23):14682-5.

[4] - Mettenburg JM, Gonias SL. Beta-amyloid peptide binds equivalently to binary and ternary alpha2-macroglobulin-protease complexes. Protein J. 2005 Feb;24(2):89-93.

[5] - LaMarre J, Wollenberg GK, Gonias SL, Hayes MA. Cytokine binding and clearance properties of proteinase-activated alpha 2-macroglobulins. Lab Invest. 1991 Jul;65(1):3-14.

[6] - French K, Yerbury JJ, Wilson MR. Protease activation of alpha2-macroglobulin modulates a 
chaperone-like action with broad specificity. Biochemistry. 2008 Jan 29;47(4):1176-85.

[7] - Lauer D, Reichenbach A, Birkenmeier G. Alpha 2-macroglobulin-mediated degradation of amyloid beta 1--42: a mechanism to enhance amyloid  beta catabolism. Exp Neurol. 2001 Feb;167(2):385-92.

[8] - Qiu WQ, Borth W, Ye Z, Haass C, Teplow DB, Selkoe DJ. Degradation of amyloid beta-protein by a serine protease-alpha2-macroglobulin complex. J Biol Chem. 1996 Apr 5;271(14):8443-51.

[9] - Du Y, Ni B, Glinn M, Dodel RC, Bales KR, Zhang Z, Hyslop PA, Paul SM. alpha2-Macroglobulin as a beta-amyloid peptide-binding plasma protein. J Neurochem. 1997 Jul;69(1):299-305.

[10] - Hughes SR, Khorkova O, Goyal S, Knaeblein J, Heroux J, Riedel NG, Sahasrabudhe S. Alpha2-macroglobulin associates with beta-amyloid peptide and prevents fibril formation. Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):3275-80.

[11] - Mettenburg JM, Gonias SL. Beta-amyloid peptide binds equivalently to binary and ternary alpha2-macroglobulin-protease complexes. Protein J. 2005 Feb;24(2):89-93.
[12] - Qiu Z, Strickland DK, Hyman BT, Rebeck GW. Alpha2-macroglobulin enhances the clearance of endogenous soluble beta-amyloid peptide via  low-density lipoprotein receptor-related protein in cortical neurons. J Neurochem. 1999 Oct;73(4):1393-8.
[13] - Misra UK, Sharma T, Pizzo SV. Ligation of cell surface-associated glucose-regulated protein 78 by receptor-recognized forms of alpha 2-macroglobulin:activation of p21-activated protein kinase-2-dependent signaling in murine peritoneal macrophages. J Immunol. 2005 Aug 15;175(4):2525-33.
[14] - Feldman SR, Ney KA, Gonias SL, Pizzo SV. In vitro binding and in vivo clearance of human alpha 2-macroglobulin after reaction with endoproteases  from four different classes. Biochem Biophys Res Commun. 1983 Jul 29;114(2):757-62.

[15] - Vassilenko A.M., Fessenko V.I., Schvets S.V. Efficacy of systemic enzyme therapy in the treatment
 of patients with chronic hepatitis B. Int. J. Immunotherapy 2001, Vol. XVII, No. 2/3/4, pp. 93-97.

[16] - Orekhov A.N., Kalenich O.S., Tertov V.V., Novikov I.D. Lipoprotein Immune Complexes As Markers of Atherosclerosis Lipoprotein Immune Complexes As Markers of Atherosclerosis. Inter. Journal of  Tissue Reactions 1991, Vol. XIII, No. 5, pp. 233-236.

[17] - Dzivite I., Sochnevs A., Stauder G., Zeibarts M., Lauga U.,4 Ansbergs J. Regular intake of Wobenzym® may prevent late complications in diabetes mellitus. Int. J. Immunotherapy 2001, Vol. XVII, No. 2/3/4, pp. 143-148- ISSN 0255-9625 218 K/375 (19-05-3).

[18] - Sledzevskaya I.K., Loboda M.V., Kolesnik E.A., Babiy L.N., Fisenko L.I. Systemic enzyme treatment as a method of secondary prevention in patients after myocardial infarction in the rehabilitation period. II Mediterranean Congress of Physical Medicine and Rehabilitation, 20-23 May, 1998, Valencia, Spain. Abstracts- pp. 137 489 KA (19-08-3).

[19] - Wrba H. Systemic Enzyme Therapy - Newest Status and Progress. Therapie Woche 1987, Jahrgang 37, No. 7  SO 11 (19-02-3).

[20] - Samtsov A.V., Mazurov V. I., Tabachnov V.V. Systemic enzyme therapy in the treatment of neurodermitis (atopic dermatitis) patients. Skin and Venereal Diseases Department of Sankt-Petersburg’s Military Medicine Academy Conference "New aspects of systemic enzyme therapy", Moscow, 1999.

[21] - Sledzevskaja U. K., Šumakov V. A., Bratus V. B., Babij A., Malinovskaja U. Z., Gavrilenko T. U., Terzov A. U. Systemic enzyme therapy in the treatment of patients with myocardial infarction. Žurnal praktièeskogo vraèa 1997, No. 3, pp. 43 – 44.

[22] - Mazourov V.I., Lila A.M., Klimko N.N., Raimuev K.V, Makulova T.G. The Efficacy of Systemic Enzyme Therapy in the Treatment of Rheumatoid Arthritis. Inter. Journal of Immunotherapy 1997, Vol. XIII, No. 3/4, pp. 85-91.

[23] - Kartvelishvili E., Shalamberidze L., Torondjadze M. The results of long-term use of Wobenzym in complex management of Behcet's disease. International congress "Advances in Immunology and Allergology at the Treshold of the XXI Century" May 3-6, 2000, Eilat, Israel.

[24] - Loginova N.S., Naumkina N.G., Sukhikh G.T. Wobenzym in therapy of various forms of fibrocystic disease with individually selected immunomodulators. International congress "Advances in Immunology and Allergology at the Treshold  of the XXI Century" May 3-6, 2000, Eilat, Israel.

[25] - Rammer E, Friedrich F. Enzyme therapy in treatment of mastopathy. A randomized double-blind clinical Study. Wien Klin Wochenschr. 1996;108(6):180-3.

[26] - F. W. Dittmarl, W. Luh. Treatment of fibrocystic mastopathy with hydrolytic enzymes. International J. of Experimental and Clinical Chemotherapie 1993: Vol. 6, No. 1, pp. 9-20 WE 13 (5-03-1) = WE 49 (5-04-1) nìm.

[27] - Sledzevskaya I.K., Loboda M.V., Kolesnik E.A., Babiy L.N., Fisenko L.I. Systemic enzyme treatment as a method of secondary prevention in patients after myocardial infarction in the rehabilitation period. II Mediterranean Congress of Physical Medicine and Rehabilitation, 20-23 May, 1998, Valencia, Spain. Abstracts- pp. 137 489 KA (19-08-3).

[28] - Sledzevskaja U. K., Šumakov V. A., Bratus V. B., Babij A., Malinovskaja U. Z., Gavrilenko T. U., Terzov A. U. Systemic enzyme therapy in the treatment of patients with myocardial infarction. Žurnal praktièeskogo vraèa 1997, No. 3, pp. 43 – 44.

[29] - Kovalenko V.N., Sledzevskaya I.K., Ryabokon E.N., Gavrilenko T.I., Terzov A.I. N.D. Strazhesko New approaches to modern cardiology based on systemic enzyme therapy. Int. J. Immunotherapy 2001, Vol. XVII, No. 2/3/4, pp. 101-111.

[30] - Mazurov V.I., Stolov S.V., Linetskaya N.E., Onyschenko E.F. Systemic enzyme therapy in the complex treatment of angina pectoris. Int. J. Immunotherapy 2001, Vol. XVII, No. 2/3/4, pp. 113-120.

[31] - Schved N.I., Martyniuk L.P. Clinico-laboratory evaluation of treatment efficacy in chronic pyelonephritis patients with Wobenzym. Vratschebnaya praktika 1997, 4, 38-42.

[32] - Schlüter. P. Phlogenzym® in patients with relapsing urinary tract infections: Efficacy & Tolerance. Schlüter. Gartenstraße 96, D-69502 Hemsbach, Germany. Report by: MUCOS Pharma GmbH & Co, Abt. Klinische Forschung, Kirchplatz 8, D-82538 Geretsried, Germany

[33] - Borisov O.V. Coenzyme metabolic assurance of patients with recurrent nephrolithiasis in the complex treatment by systemic enzyme therapy. Urologia 1998, 3, pp. 29-35.

[34] - Borisov A.V., Ukhal M.I., Kabak Yu.A., Borisov S.A. Immunological aspects of systemic enzyme therapy (SET) in the complex treatment of recurrent nephrolithiasis. 1st National Congress of the Ukraine on Immunology, Allergology, and Immunorehabilitation.

[35] - Stauder G., Wood G., Paczek L. Enzyme Therapy in Diabetic Nephropathy – Experimental and First Clinical Data. 6th Taormina Course of Nephrology. October 20th - 22th, 2000, pp. 227-232,  Editoriale Bios 2000  PZ 22 (5-14-3)-(19-11-3).

[36] - Friedrich, F.  Wobenzym® in the Treatment of Chronic Pelvic Inflammatory Disease. Study NR.: MU-89210. Germany Report provides through: PHARMASCRIPT, Kathi Kobus increase 1, W-8190 Wolf-advice-live, to Germany Report: 30. 5. 1989.

[37] - Dittmar F.-W., Weissenbacher E. R. Therapy of adnexitis - enhancement of the basic antibiotic therapy with hydrolytic enzymes. International Journal of Experimental and Clinical Chemotherapy 1992: Vol. 5, No. 2, pp. 73-81.

[38] - Nouza K. Physical activity and immune system. Systemic enzyme therapy in prevention and treatment. Medicina Sportiva Boh. Slov. 1997, Vol. 6., No. 2, pp. 41 - 45.

[39] - Wald M. Diagnosis and treatment of lymphedema. Interní medicína pro praxi 2003, č. 8, str. 415-417.

[40] - Kafková H., Kojanová M. Lymphedema.  Postgraduální medicína 2003, 5 (6), pp. 626 – 633.

[41] - Dzupina A., Morvay P., Dzupinova M. Systemic enzyme therapy and complex decongestive therapy in the patients with primary and secondary      lymphedema of lower extremity. Lymfo 2000, Praha 13. - 14. 10. 2000. Praktická flebologie - supplement 2000, Roè. IX, str. 23-27. (17-13-2)-(17-12-1).

[42] - Dusková M, Wald M. Orally administered proteases in aesthetic surgery. Aesthetic Plast Surg. 1999 Jan-Feb;23(1):41-4.

[43] - Dzupina A., Morvay P., Dzupina M. Proteolytic enzymes in lymphedema therapy. 41st Annual World Congress - ICA'99, International College of Angiology, Sapporo, Japan, July 3-10, 1999, Scientific Posters pp. 76.

[44] - Korpan MI, Fialka V. Wobenzyme and diuretic therapy in lymphedema after breast operation. Wien Med Wochenschr. 1996;146(4):67-72; discussion 74.

[45] - Kasseroller R., Wenning H.G. Efficacy and tolerability of proteolytic enzymes as an anti-inflammatory agent in lymphoedema after axillary dissection due to mammary cancer. The European Journal of Lymphology, 2002-2003, Vol. 10, No. 37-38, pp. 18-26,

[46] - Kopadze, T.Sh., Natsvlishvili, G.A., Tvaladze, M.G., Avazashvili, D.N. Application of Wobenzym and Phlogenzym to the angiology and vascular surgery. Georgian Medical News 2001, No. 2, (serial No.71), pp. 27 – 29.

[47] - Koshkin V.M., Kirienko A.I., Leontjev S.G., Agafonov V.F. Systemic enzyme therapy of lower limb postphlebitic syndrome. Angiology and vascular surgery 2000, Vol. 6, No. 2, pp. 61 – 64.

[48] - Džupina A., Džupinová M. Wobenzym in the treatment of Thrombophlebitis. Praktická flebologie 1998, Roè. 7, è. 1, str. 28-30 (17-12-3).

[49] -  Vallery M. Koshkin,, D.M.Sci. Wobenzym® in the Treatment of Acute Thrombophlebitis. PharmaScript, Kathi-Kobus-Steig 1, D-82515 Wolfratshausen, Germany.

[50] - Kvantchakhadze R.G. Wobenzym in the complex treatment of autoimmune thyroiditis. International Journal on Immunorehabilitation, 2002,  Vol. 4, No. 1, pp. 114.

[51] - Vokálová I. Systemic enzyme therapy in the treatment of children with recurrent infections of respiratory tract. VOX PEDIATRIAE 2003, Vol. 2., No. 9, pp. 29 – 30.

[52] - Shved M.I., Dubkova G.I. Therapeutic efficacy of Wobenzym in patients with focal pneumonia. Visnik naukovych doslidženij 1999, No. 2, pp. 79-82.

[53] - Mertin J.1, Stauder G., ESEMS working group. Use of oral enzymes in multiple sclerosis patients. Inter. Journal of  Tissue Reactions 1997, Vol. XIX , No.1/2, pp 95.

[54] - Krejcová, H. Wobenzym® and Wobe-Mugos® in the Treatment of Multiple Sclerosis.  PharmaScript, Kathi-Kobus-Steig 1, D-82515 Wolfratshausen, Germany.

[55] - Stauder G., Donnerstag B., Baumhackl U., Buschmans E. Use of oral enzymes in multiple sclerosis: phenotyping of peripheral blood lymphocytes from MS patients under long-term treatment with orally administered hydrolytic enzymes. Inter. Journal of Immunotherapy 1997, Vol. XIII, No. 3/4, pp 135-137.

[56] - Milus I.E. Wobenzym in the treatment of patients with psoriasis. Zurnal dermatologii i venerologii 1998, 2 (6), 35-36.

[57] - Schlüter, P. Phlogenzym® in the Treatment of Chronic Prostatitis. PharmaScript, Primelweg 2, D-82538 Geretsried, Germany Date of report: October 30th, 1997.

[58] - Schlüter P. Efficacy and tolerance of oral enzyme therapy in chronic prostatitis: Results of a double-blind therapy study. European Journal for Infectious and Immunological Diseases 1998, Vol. 2, pp. 57-69.

[59] - Izbasarov A.I., Ismoldaev E.S., Khusainov T.E. Special treatment of patients suffering from a mixed copulatory dysfunction with interoreceptive syndrome. 3rd Urology Congress of Khazakhstan May 25-26, 2000., Almaty.

[60] - Nouza K., Madar J. Immunomodulation in the treatment of reproduction disturbances. American Journal of Reproductive Immunology 2001, Vol. 46, No. 1, pp. 106.

[61] - Ivaniyta L.I., Ivaniyta S.O., Kornatskaya A.G., Belis N.I., Kondratiyk. Systemic enzyme therapy in the treatment of chronic salpingitis and infertility. Farm. Zh. (Kiev) 1998, No. 2, pp. 89-92.

[62] - Dittmar, F.-W. Enzyme therapy - a method of immune therapy for immunologically caused habitual abortion. Forum Immunologie 2000, No. 3/2000, II - VIII.

[63] - Akhtar NM, Naseer R, Farooqi AZ, Aziz W, Nazir M. Oral enzyme combination versus diclofenac in the treatment of osteoarthritis of the knee--a double-blind prospective randomized study. Clin Rheumatol. 2004 Oct;23(5):410-5. Epub 2004 Jul 24.

[64] - Klein G, Kullich W, Schnitker J, Schwann H. Efficacy and tolerance of an oral enzyme combination in painful osteoarthritis of the hip. A double-blind, randomised study comparing oral enzymes with non-steroidal anti-inflammatory drugs. Clin Exp Rheumatol. 2006 Jan-Feb;24(1):25-30.

[65] - Tilwe GH, Beria S, Turakhia NH, Daftary GV, Schiess W. Efficacy and tolerability of oral enzyme therapy as compared to diclofenac in active osteoarthrosis of knee joint: an open randomized controlled clinical trial. J Assoc Physicians India. 2001 Jun;49:617-21.

[66] - Guseinov N.I. Wobenzym in therapy of rheumatoid arthritis. International Journal on Immunorehabilitation 2001, Vol. 3, No. 2, pp. 73-74.

[67] - Shalamberidze L., Kartvelishvili E., Astvatsaturova T. The results of long-term use of Wobenzym in complex management of rheumatoid arthritis. International congress "Advances in Immunology and Allergology at the Treshold of the XXI Century" May 3-6, 2000, Eilat, Israel.

[68] - Mazourov V.I., Lila A.M., Klimko N.N., Raimuev K.V, Makulova T.G. The Efficacy of Systemic Enzyme Therapy in the Treatment of Rheumatoid Arthritis. Inter. Journal of Immunotherapy 1997, Vol. XIII, No. 3/4, pp. 85-91.

[69] - Klein G., Kullich W. Pain Reduction in Rheumatic Diseases by Oral Therapy with Enzymes. Wien. Med. Wschr. 1999, 149, pp. 577-580.

[70] - Szilasiová A., Macejová Ž., Jautová J., Pundová L. Our experience with Wobenzym in the treatment of patients with rheumatoid and psoriatic arthritis. Prakt. Lékař 1998, Vol. 78, No. 7, pp. 366-368.

[71] - Siziakina L.P., Artemenko N.A. Clinical and immunological criteria of activity of different rheumatic arthritis courses and their treatment by Wobenzym. III. Internat. Congress on Immunorehabilitation and Rehabilitation in Medicine, Eilat, Israel, 1997.

[72] - Kovalenko V.M., Golovkov Y.Z. New possibilities of basic therapy in patients with rheumatoid arthritis on the basis of systemic enzyme therapy. Reumatologia 1998, Suppl Vol. XXXVI, Warsaw 1998, Lectures No. 212, pp 110-111.

[73] - Shaivok A.V., Movsisyan G.R., Stolyarova A.V.  Wogenzym(R) in teh Treatment of Patients with Juvenile Chronic Arthritis. INt. J. Immunotherapy XIII(3/4) 93-96 (1997).

[74] - Kovalenko V.,Golovkov Y., Golovatcky I. Using of systemic enzymotherapy for treatment of rheumatoid arthritis. Rheumatologia 1998, Suppl., Vol. XXXVI, Warsaw 1998, Abst. No. 140, pp. 206.

[75] - Szilasiová A., Macejová Ž., Jautová J., Pundová L. Our experience with Wobenzym in the treatment of patients with rheumatoid and psoriatic arthritis. Prakt. Lékař 1998, Vol. 78, No. 7, pp. 366-368.

[76] - Kovalenko V.N., Golovkov Y. Z. Basic treatment of rheumatoid arthritis: new approaches. Revmatology in Europe 1997, Vol. 26, Suppl. 2, Abst. 446.

[77] - Kovalenko V.N., Siniatchenko O.V., Ignatchenko G.A., Terzov A.I., Grin V.K., Lauschkina E.M. Systemic enzyme therapy in the gout treatment. Ukrainskii kardiologitschnyi zurnal 1998: 1, 53-56.

[78] - Zuschlag J.-M. Prophylactic administration of Wobenzym to reduce consequences of sports injuries in karate fighters. MUCOS Pharma GmbH & Co, Dept. Clinical Research, Geretsried, Germany.

[79] - Kerkhoffs GM, Struijs PA, de Wit C, Rahlfs VW, Zwipp H, van Dijk CN. A double blind, randomised, parallel group study on the efficacy and safety of treating acute lateral ankle sprain with oral hydrolytic enzymes. Br J Sports Med. 2004 Aug;38(4):431-5.

[80] - Nouza K. Physical activity and immune system. Systemic enzyme therapy in prevention and treatment. Medicina Sportiva Boh. Slov. 1997, Vol. 6., No. 2, pp. 41 – 45.

[81] - Naumenko L. Yu. Use of systemic enzyme therapy in the treatment of hand injuries and their consequences. Presented at the conference ”Current treatment aspects of wrist injuries and their consequences”, Dnepropetrovsk 1998